TRVI Trevi Therapeutics, Inc.
Listings ·
Trevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million.
Trevi sold 11,600,000 shares at $13.00 each, about $150 million, below the $14.54 last sale on April 16, 2026. Its two pivotal Phase 3 trials for Haduvio are not due to report until the second half of 2027 and the first half of 2028.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $33.5 million | $39.4 million |
| Net income (loss) | -$42.8 million | -$47.9 million |
| Cash from operations | -$42.1 million | -$38.3 million |
| Cash and equivalents | $18.9 million | $34.1 million |
| Short-term investments | $169.3 million | $73.5 million |
Our latest story on this, dated Apr 16, 2026: "Trevi Therapeutics prices $150 million stock offering at $13.00 per share". The story links the filing or release it is based on. Read the story.
Trevi Therapeutics, Inc. trades under the ticker TRVI on NASDAQ.
Trevi Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Trevi Therapeutics, Inc. is 1563880. Its filings are on SEC EDGAR.
142,475,841 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Trevi Therapeutics, Inc. under United States.
Our directory classifies Trevi Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Trevi Therapeutics, Inc. is US89532M1018.
aibio.space lists Trevi Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Trevi Therapeutics, Inc. reported a net loss of $42.8 million for the fiscal year ended Dec 31, 2025, and used $42.1 million of cash in operations, per its annual report to the SEC.
$33.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$318.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Trevi Therapeutics, dated Jun 4, 2026: "Trevi Therapeutics holders approve doubling authorized shares to 400,000,000". Trevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million. Source.
Our latest listing story, dated Jun 4, 2026: "Trevi Therapeutics holders approve doubling authorized shares to 400,000,000". Trevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio